209 related articles for article (PubMed ID: 21264845)
41. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
[TBL] [Abstract][Full Text] [Related]
42. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
43. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
[TBL] [Abstract][Full Text] [Related]
44. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
[TBL] [Abstract][Full Text] [Related]
45. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
[TBL] [Abstract][Full Text] [Related]
46. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Haffty BG; Yang Q; Reiss M; Kearney T; Higgins SA; Weidhaas J; Harris L; Hait W; Toppmeyer D
J Clin Oncol; 2006 Dec; 24(36):5652-7. PubMed ID: 17116942
[TBL] [Abstract][Full Text] [Related]
47. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
48. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S; McReynolds K; Ardern-Jones A; Ahern R; Fernando I; Yarnold J; Evans G; Eccles D; Hodgson S; Ashley S; Ashcroft L; Tutt A; Bancroft E; Short S; Smith I; Gui G; ; Barr L; Baildam A; Howell A; Royle G; Pierce L; Easton D; Eeles R
Clin Cancer Res; 2006 Dec; 12(23):7033-8. PubMed ID: 17145825
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
50. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer.
Myers SP; Sevilimedu V; Barrio AV; Tadros AB; Mamtani A; Robson ME; Morrow M; Lee MK
Ann Surg Oncol; 2023 Dec; 30(13):8412-8418. PubMed ID: 37798552
[TBL] [Abstract][Full Text] [Related]
51. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy.
Møller P; Borg A; Evans DG; Haites N; Reis MM; Vasen H; Anderson E; Steel CM; Apold J; Goudie D; Howell A; Lalloo F; Maehle L; Gregory H; Heimdal K
Int J Cancer; 2002 Oct; 101(6):555-9. PubMed ID: 12237897
[TBL] [Abstract][Full Text] [Related]
52. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
[TBL] [Abstract][Full Text] [Related]
53. Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
[TBL] [Abstract][Full Text] [Related]
54. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Weideman PC; Birch KE; Hopper JL; Phillips KA
J Clin Oncol; 2013 Nov; 31(31):3920-5. PubMed ID: 24081944
[TBL] [Abstract][Full Text] [Related]
55. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Tung N; Wang Y; Collins LC; Kaplan J; Li H; Gelman R; Comander AH; Gallagher B; Fetten K; Krag K; Stoeckert KA; Legare RD; Sgroi D; Ryan PD; Garber JE; Schnitt SJ
Breast Cancer Res; 2010; 12(1):R12. PubMed ID: 20149218
[TBL] [Abstract][Full Text] [Related]
56. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
57. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
[TBL] [Abstract][Full Text] [Related]
58. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
59. Effects of
Pogoda K; Niwińska A; Sarnowska E; Nowakowska D; Jagiełło-Gruszfeld A; Siedlecki J; Nowecki Z
J Oncol; 2020; 2020():8545643. PubMed ID: 32322271
[TBL] [Abstract][Full Text] [Related]
60. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
